Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Limited Immune-Mediated Efficacy of Anti-PD-L1/VEGF in EGFR-TKI-Naïve Egfr-Mutant Lung Cancer with Non-Inflamed Tumor Microenvironment.

Current oncology (Toronto, Ont.) - 27 May 2026

Hirabae Atsuko, Kuribayashi Tadahiro, Tomida Shuta, Okawa Sachi, Nakasuka Takamasa, Nishii Kazuya, Nishimura Jun, Makimoto Go, Ninomiya Kiichiro, Higo Hisao, Rai Kammei, Ichihara Eiki, Hotta Katsuyuki, Sugimoto Masamichi, Togashi Yosuke, Maeda Yoshinobu, Kiura Katsuyuki, Ohashi Kadoaki

Abstract excerpt

Immune checkpoint inhibitors (ICIs) show limited efficacy in epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma due to its non-inflamed tumor microenvironment (TME). While quadruple therapy combining chemotherapy, anti-programmed death-ligand 1 (PD-L1), and anti-vascular endothelial growth factor (VEGF) antibodies has shown inconsistent results in EGFR-tyrosine kinase inhibitor (TKI)-pretreated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Paclitaxel

Share to Protein Kinase Inhibitors

Share to Tumor Microenvironment

Share to Vascular Endothelial Growth Factor A

Source

Open in PubMed Open full text

Identifiers

PMID: 42346215
DOI: 10.3390/curroncol33060315
PMCID: PMC13297713

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Limited Immune-Mediated Efficacy of Anti-PD-L1/VEGF in EGFR-TKI-Naïve Egfr-Mutant Lung Cancer with Non-Inflamed Tumor Microenvironment.PMID 42346215Read ↗

Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?Semantic proximity Read ↗

Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non-small cell lung cancer.Semantic proximity Read ↗

Revisiting Biomarker-Guided Therapy in EGFR-Mutant Non-Small Cell Lung Cancer with High PD-L1 Expression.Semantic proximity Read ↗

It is too Early to Say NO IMMUNOTHERAPY for EGFR‐Mutant NSCLC PatientsSemantic proximity Read ↗

Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutationsSemantic proximity Read ↗

Tumor Microenvironment Properties are Associated With Low CD68-positive Cell Infiltration and Favorable Disease-free Survival in EGFR-mutant Lung Adenocarcinoma.Semantic proximity Read ↗

Efficacy and mechanisms of immune checkpoint inhibitors in late-stage EGFR-mutated non-small cell lung cancer following targeted therapy resistance.Semantic proximity Read ↗

CD8+ T-cell Responses Are Boosted by Dual PD-1/VEGFR2 Blockade after EGFR Inhibition in Egfr-Mutant Lung Cancer.Semantic proximity Read ↗

Persist or resist: Immune checkpoint inhibitors in EGFR ‐mutated NSCLCSemantic proximity Read ↗

Tumor immune microenvironment of NSCLC with EGFR exon 20 insertions may predict efficacy of first-line ICI-combined regimenSemantic proximity Read ↗

Breaking Barriers in Lung Cancer Research: The Intriguing Connection between IL-1β and PD-1/PD-L1 PathwaysSemantic proximity Read ↗

A Randomized Phase II Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.